SAN FRANCISCO, Jan. 7, 2018 - Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that Venkateswarlu Nelabhotla (N. Venkat), co-founder and chief executive officer of Vyome, will present at the 5th Annual Dermatology Summit and the 2018 Biotech Showcase, in San Francisco.
Details for the presentations are as follows:
5th Annual Dermatology Summit
Presentation Title: Novel Antibacterials for Acne and Other Skin infections
Date/Time: Sunday, Jan. 7, 2018 at 2:15 p.m. PST
Location: Palace Hotel, San Francisco
2018 Biotech Showcase
Presentation Title: Vyome Corporate Presentation and Pipeline
Date/Time: Wednesday, Jan. 10, 2018 at 2:30 p.m. PST
Location: Hilton San Francisco Union Square
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance, and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Josephine Belluardo, Ph.D.
LifeSci Public Relations
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.